Anti-Factor Xa measurements in acute care surgery patients to examine enoxaparin dose

被引:13
|
作者
Wall, Vanessa [1 ]
Fleming, Kory, I [2 ]
Tonna, Joseph E. [3 ,7 ,8 ]
Nunez, Jade [4 ]
Lonardo, Nick [5 ]
Shipley, R. Wayne [5 ]
Nirula, Ram [4 ]
Pannucci, Christopher J. [6 ]
机构
[1] Univ Utah, Sch Med, 30 N 1900 E, Salt Lake City, UT 84132 USA
[2] Univ Utah, Div Plast Surg, 30 N 1900 E, Salt Lake City, UT 84132 USA
[3] Univ Utah, Div Cardiothorac Surg, 30 N 1900 E, Salt Lake City, UT 84132 USA
[4] Univ Utah, Div Gen Surg, 30 N 1900 E, Salt Lake City, UT 84132 USA
[5] Univ Utah, Dept Pharm Serv, 30 N 1900 E, Salt Lake City, UT 84132 USA
[6] Univ Utah, Div Hlth Serv Res, Div Plast Surg, 30 N 1900 E, Salt Lake City, UT 84132 USA
[7] Univ Utah, Crit Care, 30 N 1900 E, Salt Lake City, UT 84132 USA
[8] Univ Utah, Div Emergency Med, 30 N 1900 E, Salt Lake City, UT 84132 USA
来源
AMERICAN JOURNAL OF SURGERY | 2018年 / 216卷 / 02期
基金
美国医疗保健研究与质量局;
关键词
VENOUS THROMBOEMBOLISM PROPHYLAXIS; MOLECULAR-WEIGHT HEPARIN; CLINICAL-PRACTICE GUIDELINES; MEDICALLY-ILL PATIENTS; ED AMERICAN-COLLEGE; ACUTE BURN PATIENTS; SURGICAL-PATIENTS; TRAUMA PATIENTS; ANTITHROMBOTIC THERAPY; THROMBOSIS;
D O I
10.1016/j.amjsurg.2017.07.014
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The purpose of this study was to determine if fixed dose enoxaparin prophylaxis provided effective anticoagulation for acute care surgery patients and to examine whether a real-time enoxaparin dose adjustment algorithm optimized anticoagulation. Methods: Acute care surgical patients placed on enoxaparin prophylaxis 30 mg twice daily were recruited prospectively. Peak steady state aFXa levels were drawn with a goal peak aFXa range of 0.2-0.4 IU/ml. A real time dose adjustment algorithm was implemented for patients with out-of-range levels. Results: Fifty five patients were included. 56.4% of patients had low aFXa levels (<0.2 IU/mL). Real-time enoxaparin dose adjustment significantly increased the proportion of patients who achieved in-range peak aFXa levels, compared to standard dosing (74.5% vs 41.8%, p < 0.001). Patients with initial inadequate peak aFXa levels had a higher rate of 90-day post-operative VTE, although not statistically significant (16.1% vs. 8.3%, p = 0.50). Conclusion: The majority of acute care surgery patients receive inadequate VTE prophylaxis with fixed enoxaparin dosing. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:222 / 229
页数:8
相关论文
共 50 条
  • [1] ANTI-FACTOR Xa MEASUREMENTS IN CRITICALLY-ILL SURGICAL PATIENTS TO EXAMINE ENOXAPARIN METABOLISM AND OPTIMIZE ENOXAPARIN DOSE
    Wall, V
    Fleming, K.
    Pannucci, C.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (01) : 163 - 163
  • [2] Anti-Factor Xa Monitoring of Enoxaparin Thromboembolism Prophylaxis in Acute Care Surgery Patients: Standard Dosing Is Inadequate
    Pokrzywa, Courtney J.
    Figueroa, Juan F.
    Biesboer, Elise A.
    Morris, Rachel S.
    Trevino, Colleen M.
    Thoenes, Christopher
    De Moya, Marc A.
    Murphy, Patrick
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2022, 235 (05) : S69 - S70
  • [3] Anti-Factor Xa Monitoring of Enoxaparin Thromboembolism Prophylaxis in Emergency General Surgery Patients
    Pokrzywa, Courtney J.
    Biesboer, Elise A.
    Figueroa, Juan
    Al Tannir, Abdul Hafiz
    de Moya, Marc
    Morris, Rachel S.
    Murphy, Patrick B.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (02) : 195 - 203
  • [4] ANTI-FACTOR XA LEVELS IN PICU PATIENTS ON ENOXAPARIN FOR VENOTHROMBOEMBOLISM PROPHYLAXIS
    Marshall, Amanda
    Malone, Matthew
    Yee, Addison
    [J]. CRITICAL CARE MEDICINE, 2019, 47
  • [5] Reproducibility of the anti-Factor Xa and anti-Factor IIa assays applied to enoxaparin solution
    Martinez, Celine
    Savadogo, Adama
    Agut, Christophe
    Anger, Pascal
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2013, 81-82 : 138 - 145
  • [6] Prophylactic Enoxaparin Dosing Using Anti-Factor Xa Levels in Hepatic Surgery Patients: A Pilot Study
    Coster, Samuel
    Shammout, Ali
    Chaney, Michael
    Folkert, Kyra
    Grosh, Kent
    Shebrain, Saad
    Munene, Gitonga
    [J]. AMERICAN SURGEON, 2024, 90 (06) : 1760 - 1762
  • [7] Anti-Factor Xa Activity of Prophylactic Enoxaparin Regimens in Critically Ill Patients
    Helviz, Yigal
    Dzigivker, Ilia
    Raveh-Brawer, David
    Hersch, Moshe
    Zevin, Shoshana
    Einav, Sharon
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2016, 18 (02): : 108 - 113
  • [8] Anti-factor Xa profiles in cardiac patients receiving enoxaparin therapy.
    Tse, ME
    Mak, M
    Mitani, GH
    Pickens, P
    Beringer, PM
    Tesoro, JT
    Sarma, R
    Louie, S
    [J]. PHARMACOTHERAPY, 2005, 25 (10): : 1437 - 1437
  • [9] Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
    Tahaineh, Linda
    Edaily, Sahar M.
    Gharaibeh, Shadi F.
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2018, 10 : 63 - 70
  • [10] Anti-factor Xa Activity of Enoxaparin for Thromboprophylaxis in Nonsurgical Patients Is Dependent on Body Mass
    Jimenez, David
    Diaz, Gema
    Iglesias, Ana
    Cesar, Jesus
    Garcia-Avello, Angel
    Marti, David
    Escobar, Carlos
    Vidal, Rafael
    Sueiro, Antonio
    [J]. ARCHIVOS DE BRONCONEUMOLOGIA, 2008, 44 (12): : 660 - 663